% | $
Quotes you view appear here for quick access.


  • monty_burns92 monty_burns92 Mar 27, 2013 5:31 PM Flag

    So where's the earnings

    scheduled to report financial results for its fourth quarter and year ended December 31, 2012 on Wednesday, March 27, 2013, after the market closes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I didn't expect much "earnings" but was looking forward to signs that the introduction of LuViva is on course.
      This is what was revealed:
      “We are very pleased to be shipping eight additional LuViva devices and disposable Cervical Guides in the first quarter to our Canadian partner and are completing assembly of our first Edition 3 CE Marked units, which we anticipate shipping to Europe in the second quarter,” said Mark L. Faupel, Ph.D., Chief Executive Officer and President of Guided Therapeutics.
      “As we ramp up our manufacturing, we are targeting 15 to 20 LuViva devices to the EU and other select markets in the second quarter and currently have commitments for the units along with a significant number of disposables. Our plan is to add distribution territories in conjunction with anticipated increases in our manufacturing capacity to carefully control the product roll out market to market.
      “We also received notice of allowance of a European patent for LuViva in January,” Dr. Faupel added. “The patent covers the fundamental spectroscopy of the platform technology from which the LuViva and esophageal cancer detection products are derived. Additionally, we received notice that our clinical trial results for LuViva will be published, pending acceptance of minor revisions, in a major peer-reviewed gynecology journal later this year. We also received notification of regulatory approval in Singapore and plan to open that market and surrounding territories to sales later this year. We continue to await word from the FDA regarding LuViva, which is expected later in the spring.

0.02390.0000(0.00%)12:34 PMEDT